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Abstract 
This study evaluated the impact of manufacturing process modifications aimed at the bulk manufacture 
of curcumin implants for diabetic neuropathy pain relief. Poly (caprolactone) (PCL) and curcumin were 
blended using cryomilling as an alternative to the solvent mixing method which has higher 
manufacturing and time delay costs. X-ray diffraction (XRD) was used to characterize the resulting 
mixture to determine the efficacy of cryomilling as an option for blending curcumin and PCL powders. 
By adopting compression molding as a manufacturing method we were able to create implant molds 
featuring threaded geometry on the millirod surface. Implants were subsequently evaluated in vitro for 
30 days. Curcumin loaded millirod implants with a complex threaded surface geometry were found to 
have a higher, but not significant, percent mass loss after degradation and average daily curcumin release 
than the cylindrical implants. It can be concluded that the utilization of cryomilling for the creation of 
curcumin loaded implants in bulk is an easier to manipulate and more cost effective method of 
combining PCL and curcumin without sacrificing implant effectiveness.   
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1 Introduction 
 
Type 2 diabetes is the most prevalent form of diabetes in the United States affecting 9.3% of the 
total population (Center for Disease Control and Prevention, 2014). This form of diabetes is more 
commonly associated with obesity or lack of physical activity resulting in reduced insulin production 
and sensitivity (Rydén et al., 2007). In addition, type 2 diabetics may also suffer from additional painful 
or debilitating conditions as a result of diabetes related complications. These can include blindness, 
amputations, kidney problems, and neuropathy (Center for Disease Control and Prevention, 2014). Of 
these adverse diabetic complications, 50% of diabetics experience neuropathy in some form, which often 
manifests in foot and leg pain (Boulton et al., 2005; Dyck et al., 1993). A particular form of this 
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 condition, painful diabetic neuropathy (PDN), remains difficult to treat, as a 50% reduction in pain is 
considered a successful treatment (Huizinga & Peltier, 2007). Current solutions for PDN treatment 
include the use of cyclic antidepressants or antiepileptic drugs, both of which have negative side effects 
that may include dizziness, blurred vision, or weight gain (Huizinga & Peltier, 2007). 
Curcumin is a natural anti-inflammatory agent found naturally occurring in the spice turmeric. Many 
studies have been done to evaluate the impact of curcumin on various diseases including several 
different types of cancer (Bansal et al., 2011a; Bansal et al., 2014), asthma (Ammar et al., 2011), 
cardiovascular disease (Bronte et al., 2013), and diabetes (Chuengsamarn et al., 2012; Maradana et al., 
2013; Weisberg et al., 2008; Zhang et al., 2013). Despite the positive effects curcumin exerts as an anti-
inflammatory agent, it has been shown that curcumin has poor bioavailability when taken orally (Prasad 
et al., 2014). One option to overcome this challenge is through encapsulation of curcumin within a 
polymer matrix. This type of drug delivery is most notably used for effective birth control through 
subcutaneous implantation that provides protection for 3 years (Stoddard et al., 2011). This type of 
solution is ideal for treatment applications that require sustained treatment over a long period of time. 
As PDN is a chronic disease currently without a cure, an implantable drug delivery device would provide 
an alternative method of pain management without jeopardizing patient quality of life.   
Previous literature has developed cylindrical millirods impregnated with curcumin as a potential 
chemopreventive solution (Bansal et al., 2011a; Bansal el al., 2011b; Bansal et al., 2011c; Gupta et al., 
2012). Implants were manufactured using the solvent mixing method to create a curcumin polymer 
matrix. After removal of the solvents overnight, the molten curcumin and polymer was extruded through 
silastic tubing and cooled prior to removal from the tube. Based on the findings from Bansal et al. 
(2011c) it was confirmed that an increase in implant surface area via changes in the diameter created an 
increase in drug release rate of curcumin. This study also found that daily drug increases with 
proportional increase in drug loadings less than or equal to 10%. With that knowledge, we wanted to 
test the effects of a drastic change in implant geometry on the degradation and drug release rate of 
curcumin. However, in order to achieve this geometry an alternative method of manufacturing was 
needed. Through the use of a custom compression mold we developed a threaded cylindrical implant to 
compare against a traditional cylindrical implant. With the drastic increase in surface area it is expected 
that the threaded geometry implants will have an increased drug release rate. This experiment also looks 
to evaluate an alternative to solvent mixing of curcumin and polymers. Additionally, to minimize the 
effect of drug loading on daily average drug release, a drug loading percentage greater than 10% was 
selected. This proof of concept experiment for the threaded implant design will also be evaluated for 
future manufacturing scaling up of implants. 
2 Materials and Methods 
2.1 Materials 
Poly (caprolactone) 50,000 molecular weight was purchased from (Capa 6506, Perstorp, Sweden). 
Phosphate-buffered saline powder (pH 7.4) and bovine calf serum (BCS) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Additional BCS was purchased from Hyclone (Logan, UT, USA). 
Curcumin (98% pure) was purchased from Acros Organics (Morris Plains, NJ, USA). No further 
analysis was done on any of the received materials. 
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2.2 Methods 
2.2.1 Cryomilling 
PCL was combined with curcumin at a 15% w/w ratio. Milling was done using a SPEX Sample Prep 
Freezer Mill 6770 (Metuchen, NJ, USA). PCL and curcumin were combined in a grinding vial and 
placed in the grinding chamber. The vial was precooled for 15 minutes prior to the start of grinding 
cycles. The mill was programmed for 5 cycles, a 2 minute cool time, and a 3 minute run time at a rate 
of 10 cps. 
 
2.2.2 XRD Evaluation of Cryomilled PCL and Curcumin 
In order to determine if the cryomilling process generated a homogeneous mixture of PCL and 
curcumin, XRD analysis was done over a full angle spectrum in a Rigaku Miniflex 600 XRD analysis 
unit (Tokyo, Japan). The voltage and current X-ray generator applied were 40 kV and 15 mA 
respectively. A scintillation counter (SC-70) was used as the detector. Scan range was from 1.01 to 60 
degrees at a step width of 0.02 degrees. The XRD profiles were analyzed using the integrated X-ray 
powder diffraction software, PDXL, version 2.1.3.4. 
 
2.2.3 Compression Molding 
Implants were created using two custom molds. The cylindrical rod mold created implants with a 2 
mm diameter, while the threaded rod mold (Figure 1) had an implant diameter of 1.5 mm in order to 
accommodate machining capabilities for the introduction of threads. Molds were loaded into a model 
4386 model Carver hydraulic press (Wabash, IN, USA). Blank PCL implants were created using 50,000 
molecular weight PCL at a plate temperature of 71° C. Curcumin loaded PCL implants were created 
using the cryomilled PCL and curcumin at a plate temperature of 71°C and compressed with 1,200 psi.  
Implants were removed from the molds and separated from the mold stem before evaluation. Implants 
for both geometries were cut to a length of 1.30 cm. The average threaded implant mass was 22.0 ± 0.75 
mg and the average cylindrical implant was 49.9 ± 1.04 mg. 
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 Figure 1. Threaded compression mold design with inset to show thread detail.  
2.2.4 In Vitro Evaluation 
Implants were studied in vitro by submerging each sample (n=3 for each condition, 12 total implants) 
in 10 mL of PBS solution (pH 7.4) in 20 mL amber vials. In order to better mimic the in vivo 
environment, the PBS was supplemented with BCS (10% v/v). The sample implants were incubated at 
37° C and agitated at 150 rpm on a shaker table (I24 New Brunswick Incubator Shaker, Eppendorf, 
Germany). Samples were measured at every media change every 48 hours due to the slow nature of PCL 
degradation in vitro (Lam et al., 2008). 
2.2.5 Spectrophotometer Characterization 
In order to validate curcumin was present in degradation media, 1 mL of ethanol was added to media 
to solubilize residual curcumin. Absorbance of the media was measured spectrophotometrically (DU 
720, Beckman Coulter, CA, USA) at 430 nm as previously established (Priyadarsini, 2009).  A standard 
curve was used to determine the quantitative relationship between absorbance values and curcumin 
concentration present in the degradation media. Curcumin concentration range was from 100 μg-700 
μg. 
 
2.2.6 Scanning Electron Microscopy (SEM) 
Evaluation of surface area features and the effects of degradation on physical properties of implants 
was studied using a Jeol JCM-6000 benchtop SEM (Tokyo, Japan). Implants were evaluated prior to in 
vitro degradation and after 30 days of degradation. Samples were mounted using carbon tape and 
analyzed at 15 kV. 
 
2.2.7 Statistical Analysis 
Percent mass loss values were analyzed using a two way ANOVA with significance set at p < 0.05. 
Statistical significance for average daily drug release was determined using a standard two tailed t-test. 
Differences were considered significant for values where p < 0.05.  Normal distribution and equal 
variances were assumed. 
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 3 Results 
3.1 XRD Evaluation of Cryomilled PCL and Curcumin 
Figure 2 shows the XRD profile for the cryomilled PCL and curcumin at an 85% to 15% ratio 
respectively. Comparison peaks for 100% curcumin and 100% PCL are also shown in Figure 2. This 
result shows that PCL and curcumin mixture has a distinct profile curve unique from its constituent 
parts. Figure 3 shows the XRD analysis of a solvent mixed matrix of PCL and curcumin in the same 85-
15% ratio. There were a few differences in the XRD characteristic peaks of the cryomilled curcumin 
and PCL powder in comparison to the solvent mixed PCL and curcumin solid dispersion. 
Figure 2. XRD profiles of 85% PCL and 15% curcumin in relation to neat PCL and curcumin profiles. 
 
Figure 3. XRD profiles of cryomilled 85% PCL and 15% curcumin in comparison to solvent mixed 
PCL and curcumin in the same ratio. 
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 3.2 In Vitro Results 
In vitro release profiles for both the original cylindrical geometry and the new threaded geometry 
implants without drug loading can be found in Figure 4. Due to drastically different geometries, the 
starting masses for the threaded and cylindrical implants were not directly comparable by mass loss. 
Instead, percent mass loss was used to analyze changes in implant weight. There was no significant 
difference in the average percent weight loss over 30 days of degradation between the two geometries 
without curcumin loading. All data is presented as mean ± SD. A comparison of the percent mass loss 
between curcumin loaded PCL cylindrical millirods and blank PCL cylindrical implants the percent 
mass loss observed in the curcumin loaded geometry (1.59 ± 0.884) was not significantly different from 
that of the blank PCL rod mass loss (0.813 ± 0.399). Similarly, a comparison of blank threaded PCL 
implants (0.837 ± 0.62) to curcumin loaded PCL threaded implants (3.39 ± 1.31) did not have a 
significantly higher average percent mass loss over the PCL only sample. Lastly, a comparison of 
average cumulative mass loss for curcumin loaded implants with threaded and cylindrical geometries 
shows that the curcumin loaded threaded geometry (3.39 ± 1.31) did not have a significantly higher 
percent mass loss over 30 days than the cylindrical geometry implant with curcumin (1.59 ± 0.884). 
Table 1 shows the ANOVA results for the percent mass loss data. No interactions were found to be 
significant at a sample size of three. Figure 5 shows sample daily percent mass loss trends for the two 
curcumin loaded implants with different geometries. 
Figure 4. Graph of percent mass loss findings and standard error across all groups. 
 
Table 1. ANOVA of Cumulative Mass Loss Percentages (n=3) 
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Figure 5. In vitro release profiles over 30 days of degradation by percent mass loss with standard error 
bars for 15% curcumin loaded implants between the two different geometry types. 
 
3.3 Spectrophotometry Characterization 
The results of the spectrophotometry characterization can be found in Figure 6. Using the standard 
curve to relate absorbance values to μg/day release found that the threaded geometry implant had a 
significantly higher average daily release than the cylindrical geometry after accounting for mass 
differences.  Threaded geometry implants released an average of 47.98 ± 0.11 μg/day, while cylindrical 
geometry implants released 33.00 ± 0.06 μg/day (data presented as mean ± SD). 
 
 
 
Figure 6. Average daily curcumin release values and standard error bars over the course of 30 days 
in vitro degradation. * denotes statistical significance. 
 
 
Bulk Manufacture of Complex Geometry Millirod Implants and Their Degradation and Drug Delivery
Characteristics Melissa Slagle and Iris Rivero
472
 3.4 SEM Analysis 
Scanning electron microscope analysis of both cylindrical and threaded millirods can be found in 
Figure 7. After in vitro degradation a noticeable change in surface morphology was observed in both 
geometry types. At 30 days of degradation the cylindrical implant began showing signs of small surface 
holes where there were none previously.  
Estimated threaded implant surface area was calculated using the following equation (Sharp 
Corporation, 2012): 
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Where a is the inner thread diameter, b is the outer thread diameter, c is the pitch length, and d is the 
length of the implant. Surface area for the threaded geometry implant was found to be 72.4 mm2. 
 
Figure 7. SEM images for sample millirods before and after in vitro degradation. (A) Cylindrical 
curcumin loaded millirod implant before degradation. (B) Cylindrical curcumin loaded millirod after 30 
days of in vitro degradation. (C) Threaded curcumin loaded implant prior to degradation. (D) Threaded 
curcumin loaded implant after 30 days of degradation. 
 
 
A B 
C D 
Bulk Manufacture of Complex Geometry Millirod Implants and Their Degradation and Drug Delivery
Characteristics Melissa Slagle and Iris Rivero
473
 4 Discussion 
Solvent mixing has been the primary method for creating the polymer drug matrix. However, this 
method requires additional materials in the form of solvents to dissolve the drug and the polymer, as 
well as time to remove the solvent from the mixture after the drug and polymer were combined. This is 
usually done overnight in a vacuum environment. The end product is a solid curcumin and polymer 
mass that must undergo additional processing prior to being converted into its final form. Removing 
solvents from the polymer matrix creation would reduce manufacturing material costs in addition to a 
reduction in material processing time. Cryomilling can be executed in minutes rather than hours, and 
the end product is a powder that is easy to introduce into molding or extruding applications. A 
comparison of the XRD profiles for both solvent mixed and cryomilled PCL and curcumin shows similar 
overall trends. However, near the 10 degree mark the cryomilled mixture has a defined peak not present 
in the solvent mixed sample. This peak is a reduced intensity version of the curcumin characteristic peak 
that appears at the same degree. This retention of a main characteristic peak for curcumin may point to 
a better method of mixing without compromising the compound integrity. A study by Wegiel et al. 
(2014) utilized cryomilling as a method to create larger quantities of amorphous curcumin and poly 
(vinylpyrrolidone) mixtures. From this we can conclude that cryomilling serves as an effective 
alternative method for creating a powder polymer matrix in bulk manufacturing quantities. Previous 
work established by Bansal (2011c) established homogeneity of implants via dissolution in 
dichloromethane and measurement of the amount of residual drug via UV spectrophotometry. Although 
this method validates drug loading concentration, it does not speak to the mixture profile in the solid 
implant form. Future work needs to establish an effective method for characterizing implant 
homogeneity in the implant form. Future studies will also directly compare the drug release rates of 
cryomilled implants and solvent mixed implants.  
The use of silastic tubing works well for small scale production of implants with a basic cylindrical 
geometry. Based on previous literature, modification of surface area is a way to increase drug release 
rate, but use of tubing limits changes to modifying diameter size and production volume. The use of a 
mold would allow for production of 8-12 implants at a time in addition to the potential incorporation of 
new surface geometries with a reduced amount of materials consumed during the process. Both the 
cylindrical and threaded geometry implants for this study were created through the use of a mold. This 
allowed for minimal post manufacturing processing while allowing for the addition of complex surface 
geometry to the threaded implants that was previously not attainable. 
In vitro degradation of the cylindrical geometry in comparison to the threaded geometry without 
drug loading was not statistically significant.  By comparing each drug loaded implant geometry type to 
its respective blank implant counterpart it was determined that increased surface geometry in 
combination with curcumin loading was not significant for percent mass loss degradation. Both the 
curcumin loaded cylindrical implant and the curcumin loaded threaded implant showed greater percent 
mass loss degradation than the blank PCL implants, however, due to the small sample size statistical 
significance was not obtained..  
A comparison of the curcumin loaded cylindrical implant and the curcumin loaded threaded implant 
showed the threaded geometry had a 46.9% greater percent mass loss over the cylindrical geometry 
during degradation. However, an analysis of variance was run on the average percent mass loss values 
and showed no significant values at p < 0.05 indicating that a larger sample size is required to confirm 
that drug loading is a statistically significant parameter. Analysis of the percent mass loss from Figure 
6 indicates a steady decreasing trend over the 30 day period. No burst release kinetics were observed 
for either implant geometry. SEM analysis of the threaded implants before and after degradation show 
that the threaded surface geometry was still present and visible after 30 days of degradation. Surface 
area for the threaded geometry implant was 72.4 mm2, which is a 9.3% increase in surface area over a 
cylindrical implant of the same diameter.  
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Spectrophotometer analysis of the degradation serum showed after accounting for differences in 
implant masses that the threaded geometry implants had a higher average μg/day release than the 
cylindrical geometry. This confirms the hypothesis that an increase in surface geometry would increase 
the drug release rate. A 100 mg cylindrical implant with a diameter of 3.22 mm and a 20% drug load 
created by Gupta et al. (2012) had an average daily release of 98 µg/day and a cumulative release of 
9.8% in 20 days. Implants created for this study were not directly comparable to the previous findings 
due to differences in weight, volume, and drug load. However, extrapolation of mass and drug loading 
of the cylindrical geometry to better match the previous study gave an average daily release of ~70 
μg/day. Differences in implant length and diameter would create significant differences in implant 
volume from the comparison implant and may account for discrepancies in average daily release 
between the two studies. 
By using bulk manufacture of implants a cost savings could be imparted on the consumer. However, 
bulk manufacture limits the amount of customization available for the patient at the point of 
manufacture. Rather, customization for an individual patient would happen at the point of implantation. 
Customization could include the number of implants needed, the site of implantation, or post 
manufacturing modification, such as a change in implant length, to better meet patient dosing needs to 
manage neuropathy pain. The implant would be best utilized as an adjunct treatment to tricyclic 
antidepressants and antiepileptic drugs, or as a standalone pain relief option for patients intolerant or 
unaffected by current drug therapies.  
5 Conclusions 
There is a current need for additional treatment solutions to help manage the symptoms of PDN 
without the negative side effects of the current off label prescribed drugs. Curcumin presents an 
attractive anti-inflammatory agent and glycemic regulator, but is plagued by low bioavailability when 
taken orally. By altering the shape geometry through the introduction of threads, an increase in percent 
mass loss, although not statistically significant at this sample size, was observed for curcumin loaded 
implants. The threaded geometry implants also showed a higher μg/day release of curcumin in vitro than 
their cylindrical counterparts. By modifying previously used manufacturing methods, this threaded 
geometry feature for subcutaneous implants can be easily scaled up for larger manufacturing needs. 
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